← Who reports today · Health Care
EW earnings date & Q2 2026 results · Edwards Lifesciences
US GAAP · $M · vs Q2 2025 · quarter ended 06/30/2026 · reported 07/23/2026
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. · Text: Wikipedia, CC BY-SA 4.0, abridged
More about the company
The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
Key growth driver: Revenue growth of +14% y/y — the report gives no segment split, so the driver is the whole business. · by the Q2 2026 report
When is EW’s next earnings date?
Thursday, October 29, 2026estimated
Expected around Oct 29 — based on last year’s report on Oct 30, 2025. We have not yet seen the company's announcement of the date.
How we estimate
The estimate is the date of the same-quarter report a year ago, per the company’s SEC filing, moved forward 52 weeks (same weekday). Companies usually keep the same week; the date will be replaced once EW announces it.
Same quarter a year ago (ended September 30, 2025): revenue $1.553B, EPS (GAAP) $0.50
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
What time does EW report? Usually after market close: the last 4 results releases reached the SEC at 4:29 pm, 4:20 pm, 4:22 pm, 4:18 pm ET.
Last report: Jul 23, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates: company announcements; past dates and times — SEC 8-K filings. Who else reports this week →
All figures in $M.
Revenue
$1,741
+13.6%
Gross profit
$1,349
+13.5%
77.5% margin
Operating income
$513
+24.8%
29.5% margin
Net income
$242
−27.4%
$0.42/sh · 13.9% margin
Verdict: revenue grew 13.6% y/y to $1.74B, operating margin 29.5% vs 26.8%, net income $242M (−27.4% y/y).
Source and notation
Source: Edwards Lifesciences press release, 8-K EX-99.1 of 07/23/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Heads-up
- net income fell 27% y/y in Q2 2026
Most likely because gross margin was 77.5% vs 77.5% a year earlier; the effective tax rate was 53.6% vs 16.1% a year earlier; costs grew faster than revenue (provision for income taxes +333% y/y). Based on the Q2 2026 report.
The company's report ↗EW earnings history: past report dates
| Jul 23, 2026 Thu | 4:29 pmafter market close | Jun 30, 2026 | $1.7B+14% y/y | $0.42−25% y/y |
| Apr 23, 2026 Thu | 4:20 pmafter market close | Mar 31, 2026 | $1.6B+17% y/y | $0.66+8% y/y |
| Feb 10, 2026 Tue | 4:22 pmafter market close | Dec 31, 2025 | ≈$1.6B+13% y/y | ≈$0.16−75% y/y |
| Oct 30, 2025 Thu | 4:18 pmafter market close | Sep 30, 2025 | $1.6B+15% y/y | $0.50−90% y/y |
| Jul 24, 2025 Thu | 4:23 pmafter market close | Jun 30, 2025 | $1.5B+12% y/y | $0.56−8% y/y |
| Apr 23, 2025 Wed | 4:33 pmafter market close | Mar 31, 2025 | $1.4B+6% y/y | $0.61+5% y/y |
| Feb 11, 2025 Tue | 4:24 pmafter market close | Dec 31, 2024 | $1.4B+9% y/y | $0.65+7% y/y |
| Oct 24, 2024 Thu | 4:28 pmafter market close | Sep 30, 2024 | $1.4B+9% y/y | $5.13+714% y/y |
| Jul 24, 2024 Wed | 4:26 pmafter market close | Jun 30, 2024 | $1.4B+7% y/y | $0.61+22% y/y |
| Apr 25, 2024 Thu | 4:23 pmafter market close | Mar 31, 2024 | $1.3B+9% y/y | $0.58+4% y/y |
| Feb 6, 2024 Tue | 4:23 pmafter market close | Dec 31, 2023 | $1.3B+195% y/y | $0.61−6% y/y |
| Oct 25, 2023 Wed | 4:32 pmafter market close | Sep 30, 2023 | $1.2B−6% y/y | $0.63+15% y/y |
| Jul 26, 2023 Wed | 4:22 pmafter market close | Jun 30, 2023 | $1.3B−7% y/y | $0.50−23% y/y |
| Apr 26, 2023 Wed | 4:29 pmafter market close | Mar 31, 2023 | $1.2B−9% y/y | $0.56−5% y/y |
| Jan 31, 2023 Tue | 4:31 pmafter market close | Dec 31, 2022 | ≈$430M−68% y/y | ≈$0.65+23% y/y |
| Oct 27, 2022 Thu | 4:21 pmafter market close | Sep 30, 2022 | $1.3B+1% y/y | $0.55+2% y/y |
Show all 16 reports since 2022Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Edwards Lifesciences: 15-year financials
| 2025 | 6,068 | 1,264 | 1,074 | 1,335 |
| 2024 | 5,440 | 1,379 | 4,175 | 290 |
| 2023 | 5,010 | 1,309 | 1,402 | 643 |
| 2022 | 4,464 | 1,498 | 1,522 | 974 |
| 2021 | 5,233 | 1,690 | 1,503 | 1,406 |
| 2020 | 4,386 | 898 | 823 | 647 |
| 2019 | 4,348 | 1,147 | 1,047 | 929 |
| 2018 | 3,723 | 748 | 722 | 688 |
| 2017 | 3,435 | 1,089 | 584 | 833 |
| 2016 | 2,964 | 751 | 570 | 528 |
| 2015 | 2,494 | — | 495 | 447 |
| 2014 | 2,323 | — | 811 | 939 |
| 2013 | 2,046 | — | 389 | 364 |
| 2012 | 1,900 | — | 292 | 241 |
| 2011 | 1,679 | — | 237 | 232 |
Show all 15 yearsShow fewer
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Shareholders’ equity at Jun 30, 2026: $10.6B (77% of total assets). Compare with other S&P 500 companies →
Included in screener lists: S&P 500 companies with no net debt
Edwards Lifesciences (EW) earnings: FAQ
When is EW's next earnings date?
We have not yet seen an announcement of the date from Edwards Lifesciences (EW). Based on last year's report on Oct 30, 2025, the next report is expected around Oct 29, 2026.
What time does EW report earnings?
Edwards Lifesciences usually reports after market close: its latest results release was filed with the SEC at 4:29 pm ET on Jul 23, 2026.
When did EW last report earnings?
Edwards Lifesciences reported Q2 2026 results on Jul 23, 2026.
Where can I find Edwards Lifesciences's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to EW's filings; this page breaks the latest report down in a Sankey chart.
What was EW's net income in Q2 2026?
Edwards Lifesciences reported net income of $242M for Q2 2026 (−27.4% year over year), under US GAAP.
How has Edwards Lifesciences's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.6x: $1,679M in 2011 and $6,068M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report — two independent automated readings of the release had to match, and every number in the text was checked against it. Figures checked against the filing on 10/16/2026. How we make the breakdowns · Report an error
More reports: GEHC · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · HSIC · Q2 2026 · HUM · Q2 2026 · IDXX · Q2 2026 · ILMN · Q2 2026 · INCY · Q2 2026 · IQV · Q2 2026 · ISRG · Q2 2026 · all reports